Modafinil as adjunctive therapy in depressed outpatients

Annals of Clinical Psychiatry

Volumn 16, Issue 3, 2004, Pages 133-138

  Nasr, Suhayl ^a  

^a Nasr Psychiatric Services   (United States)

Author keywords

Adjunct; Depression; Fatigue; Modafinil; Sleepiness; Wakefulness

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; CLONAZEPAM; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LEVOTHYROXINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; RIVASTIGMINE; SERTRALINE; VALPROATE SEMISODIUM; VENLAFAXINE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG USE; ELECTROCONVULSIVE THERAPY; FATIGUE; HEADACHE; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; HYPOMANIA; HYPOTHYROIDISM; IRRITABILITY; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOTHERAPY; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TREMOR; VISUAL ANALOG SCALE; WAKEFULNESS;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER, MAJOR; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WAKEFULNESS;

EID: 4644290383     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1080/10401230490486954     Document Type: Article

References (30)

1. American Psychiatric Association: Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157(4 suppl):1-45.
2. Heninger GR, Charney DS, Sternberg DR: Lithium carbonate augmentation of antidepressant treatment: An effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983; 40:1335-1342.
3. Schopf J, Bauman P, Lemarchand T, Rey M: Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: Results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989; 22:183-187.
4. Joffe RT, Singer W, Levitt AJ, MacDonald C: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387-393.
5. Stein G, Bernadt M: Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162:634-640.
6. Katona CL, Abou-Saleh MT, Harrison DA, Nairoc BA, Edwards DR, Lock T, Burns RA, Robertson MM: Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166:80-86.
7. Bauman P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M: A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16:307-314.
8. Nelson JC: Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61:13-19.
9. Littner M, Johnson SF, McCall WV, Anderson WM, Davila D, Hartse K, Kushida CA, Wise MS, Hirshkowitz M, Woodson T: Practice parameters for the treatment of narcolepsy: An update for 2000. Sleep 2001; 24:451-466.
10. Bastuji H, Jouvet M: Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Bio Psychiatry 1988; 12:695-700.
11. Broughton RJ, Fleming JAE, George CFP, Hill JD, Kryger MH, Moldofsky H, Montplaisir JY, Morehouse RL, Moscovitch A, Murphy WF: Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49:444-451.
12. Arnulf I, Homeyer P, Garma L, Whitelaw WA, Derenne J-P: Modafinil in obstructive sleep apnea-hypopnea syndrome: A pilot study in 6 patients. Respiration 1997; 64:159-161.
13. U.S. Modafinil in Narcolepsy Multicenter Study Group: Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43:88-97.
14. U.S. Modafinil in Narcolepsy Multicenter Study Group: Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54:1166-1175.
15. Pack AI, Black JE, Schwartz JRL, Matheson JK, for the U.S. Modafinil in Obstructive Sleep Apnea Group: Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164:1675-1681.
16. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld A, Pollak CP, Nagaraja HN: Efficacy and safety of modafinil (PROVIGIL®) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72:179-183.
17. Menza MA, Kaufman KR, Castellanos A: Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61:378-381.
18. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with Major Depressive Disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64:1057-1064.
19. Carroll BJ, Feinberg M, Smouse PE, Rawson SG, Greden JF: The Carroll Rating Scale for depression I. Development, reliability and validation. Br J Psychiatry 1981; 138:194-200.
20. Nasr SJ, Altman EG, Rodin MB, Jobe TH, Burg B: Correlation of the Hamilton and Carroll Depression Rating Scales: A replication study among psychiatric outpatients. J Clin Psychiatry 1984; 45:167-168.
21. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: National Institute of Mental Health, US Department of Health, Education, and Welfare, 1976.
22. Terzoudi M, Gavrielidou P, Heilakos G, Visviki K, Karageorgio CE: Fatigue in multiple sclerosis; evaluation and a new pharmacological approach. Neurology 2000; 54 (Suppl 3):A61-62.
23. DeBattista C, Lembke A, Solvason B, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacology 2003; 24:87-90.
24. Lin JS, Hou Y, Jouvet M: Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996; 93:14126-14133.
25. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, Saper CB: Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20:8620-8628.
26. Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C: Long-term efficacy and safety of modafinil (Provigil) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000; 1:231-243.
27. Warot D, Corruble E, Payan C, Weil JS, Puech: Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: A comparison with amphetamine, caffeine and placebo. Eur Psychiatry 1993; 8:201-208.
28. Jasinski DR: An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000; 14:53-60.
29. Jasinski DR, Kovacevic-Ristanovic R: Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000; 23:149-156.
30. Emsellem HA and the US Modafinil Study Group: Efficacy and safety profiles of PROVIGIL® (modafinil) maintained during long-term (40 and 88 weeks) treatment of excessive daytime sleepiness associated with narcolepsy. Neurology 2000; 54(suppl 3):A29-30.